Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and the effect on disease activity of Tocilizumab in Patients with Active Rheumatoid arthritis on background non-biologic DMARDs who have an inadequate response to current non-biologic DMARD and/or Anti- TNF therapy.
Phase of Trial: Phase IV
Latest Information Update: 23 Sep 2014
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 06 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.